Polymerized α1-antitrypsin is present on lung vascular endothelium.: New insights into the biological significance of α1-antitrypsin polymerization

被引:24
作者
Aldonyte, R
Jansson, L
Ljungberg, O
Larsson, S
Janciauskiene, S
机构
[1] Malmo Univ Hosp, Wallenberg Lab, Dept Med, S-20502 Malmo, Sweden
[2] Malmo Univ Hosp, Dept Pathol, S-20502 Malmo, Sweden
[3] AstraZeneca, Res & Dev, Lund, Sweden
关键词
alpha(1)-antitrypsin; COPD; endothelial cells; polymers;
D O I
10.1111/j.1365-2559.2004.02021.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: The damage to lung tissue in chronic obstructive pulmonary disease (COPD) may involve the progressive loss of pulmonary vascular endothelial cells. Endothelial binding of alpha1-antitrypsin (alpha(1)-AT) derived from plasma has been identified, and alpha(1)-AT deficiency is a known genetic risk factor associated with alpha(1)-AT polymerization and COPD development. Therefore, in the present study we aimed to investigate if alpha(1)-AT is present on the lung vascular endothelium, and if it is in a polymeric form. Methods and results: Postmortem paraffin-embedded tissue specimens from 15 COPD (chronic bronchitis and emphysema) cases with and without Z alpha(1)-AT (Glu342Lys) deficiency and from 10 cases without signs of COPD were studied. Immunohistochemistry was performed using the streptavidin-biotin method with a monoclonal ATZ11 antibody specific for polymeric alpha(1)-AT, and polyclonal antibodies against human alpha(1)-AT and neutrophil elastase. Vascular endothelium showed intense staining for alpha(1)-AT with the ATZ11 antibody in all cases; however, intensity of staining in patients with alpha(1)-AT deficiency was greater. No endothelial staining was observed with the anti-elastase antibody. Conclusions: This is the first demonstration that alpha(1)-AT bound to the vascular endothelium of lungs is in a polymeric form, which also suggests a possible previously unknown role for polymeric alpha(1)-AT in vivo.
引用
收藏
页码:587 / 592
页数:6
相关论文
共 33 条
[1]   CIGARETTE-SMOKING AND OXIDATIVE DAMAGE IN THE LUNG [J].
CHOW, CK ;
RYLANDER, R ;
PRYOR, W .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES-SERIES, 1993, 686 :289-298
[2]  
Cines DB, 1998, BLOOD, V91, P3527
[3]   A kinetic mechanism for the polymerization of α1-antitrypsin [J].
Dafforn, TR ;
Mahadeva, R ;
Elliott, PR ;
Sivasothy, P ;
Lomas, DA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (14) :9548-9555
[4]   Carcinogenesis of primary liver malignancies [J].
Dürr, R ;
Caselmann, WH .
LANGENBECKS ARCHIVES OF SURGERY, 2000, 385 (03) :154-161
[5]   Topography of a 2.0 Å structure of α1-antitrypsin reveals targets for rational drug design to prevent conformational disease [J].
Elliott, PR ;
Pei, XY ;
Dafforn, TR ;
Lomas, DA .
PROTEIN SCIENCE, 2000, 9 (07) :1274-1281
[6]  
Eriksson Sten, 1999, Journal of Hepatology, V30, P34
[7]   Chronic liver disease in heterozygous α1-antitrypsin deficiency PiZ [J].
Fischer, HP ;
Ortiz-Pallardó, ME ;
Ko, Y ;
Esch, C ;
Zhou, H .
JOURNAL OF HEPATOLOGY, 2000, 33 (06) :883-892
[8]  
FORSYTH KD, 1994, CLIN EXP IMMUNOL, V95, P277
[9]  
HALE KA, 1980, AM REV RESPIR DIS, V122, P273
[10]   Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with α1-antitrypsin deficiency (PiZ) [J].
Hill, AT ;
Campbell, EJ ;
Bayley, DL ;
Hill, SL ;
Stockley, RA .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (06) :1968-1975